BerGenBio ASA Alternatives & Competitors

12 companies similar to BerGenBio ASA — Developing Innovative Drugs for Aggressive Diseases

Prescient Therapeutics

A clinical stage oncology company developing personalised medicine approaches to cancer; c...

14 Post-IPO Equity $3.00M

Australia

Biopharma Biotechnology +3

Senex Biotechnology. Inc.

Preventing Adaptive Drug Resistance and Cancer Metastasis

5 Debt Financing $600.00K

Biotechnology Health and Wellness +1

Advenchen Laboratories, LLC

Pioneering novel therapies with promising small molecule kinase inhibitors for a brighter...

6 Venture round $4.48M

Biotechnology Health Care +1

ORIC Pharmaceuticals Inc.

Overcoming Resistance In Cancer

119 Post-IPO Equity $408.00M

South San Francisco, Unit...

Biopharma Biotechnology +3

Track all BerGenBio ASA competitors

Get real-time alerts when any of these companies raise funding, hire, or show growth signals.

See how it works

Biond Biologics Ltd

Biond - Innovative immunotherapies and a pioneering intracellular delivery for biologics f...

43 Series C $32.00M

Israel

Biotechnology Health Care +1

Forma Therapeutics

Dedicated to transforming the lives of patients with rare hematologic diseases and cancers...

159 Series D $142.50M

Watertown, United States

Biotechnology Health Care +1

Lixte Biotechnology Holdings, Inc.

Lixte Biotechnology (Nasdaq: LIXT)

6 Post-IPO Equity $10.48M

United States

Biotechnology Health Care +1

NEOGAP Therapeutics AB

Science for cure.

28 Grant $147.66M

Stockholm, Sweden

Biotechnology Health Care +1

KeifeRx

KeifeRx is a biopharmaceutical company finding disease-modifying treatments for neurodegen...

7 Series A $6.00M

Mclean, United States

Biopharma Biotechnology +1

Tetralogic Pharmaceuticals

10 Convertible Note $164.00M

Biotechnology Health Care +1

GLG Pharma

Why Show the GSK Compound? Because the cancer cells become resistant. How? By STAT3! GLG's...

3 Venture round

Jupiter, United States

Biotechnology Health Care +1

Adastra Pharmaceuticals

Adastra is committed to transforming cancer care.

11-50 Venture round $85.00M

Princeton, United States

Biotechnology Health Care +1

About BerGenBio ASA

BerGenBio ASA is a clinical-stage biopharmaceutical company founded in 2007 and headquartered in Norway. The company is dedicated to developing innovative drugs for aggressive diseases. BerGenBio is focused on creating a pipeline of first-in-class selective AXL kinase inhibitors to treat multiple aggressive cancers.

Business keywords

Biopharmaceutical, Drug Development, Clinical-stage, Cancer Treatment, AXL Kinase Inhibitors, Aggressive Cancers, Immune Evasion, Drug Resistance, Cancer Research, Therapeutic Options, Innovative Drugs

Frequently Asked Questions

Companies similar to BerGenBio ASA include Prescient Therapeutics, Senex Biotechnology. Inc., Advenchen Laboratories, LLC, ORIC Pharmaceuticals Inc., Biond Biologics Ltd. They work in Biotechnology and Pharmaceutical and share BerGenBio ASA's focus on drug development, cancer treatment and cancer research.

Bounce Watch lists 12 companies that share BerGenBio ASA's industries and are closest to it in business tags, services, target customers, business model and size.

Don't just read about them. Follow them.

BounceWatch watches BerGenBio ASA and millions of other companies. When one raises money, hires quickly or changes its product, we tell you the same day.

See how it works

Explore Related

BerGenBio ASA Profile Prescient Therapeutics Alternatives Senex Biotechnology. Inc. Alternatives Advenchen Laboratories, LLC Alternatives All Companies All Signals Trend Reports

Compiled from the BounceWatch company index. We last looked at BerGenBio ASA on 12 Sep 2024. The 12 companies listed here were last checked between 11 Sep 2024 and 11 Mar 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.